Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX – Get Free Report) shares traded down 1.8% during mid-day trading on Wednesday . The company traded as low as $0.80 and last traded at $0.81. 1,251 shares were traded during mid-day trading, a decline of 87% from the average session volume of 9,554 shares. The stock had previously closed at $0.83.
Eloxx Pharmaceuticals Stock Performance
The business has a fifty day simple moving average of $0.93 and a 200-day simple moving average of $1.15. The firm has a market cap of $2.54 million, a price-to-earnings ratio of -0.09 and a beta of 2.75.
Hedge Funds Weigh In On Eloxx Pharmaceuticals
An institutional investor recently bought a new position in Eloxx Pharmaceuticals stock. Armistice Capital LLC bought a new position in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX – Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 275,000 shares of the company’s stock, valued at approximately $1,323,000. Armistice Capital LLC owned approximately 10.00% of Eloxx Pharmaceuticals as of its most recent SEC filing. 2.90% of the stock is owned by institutional investors and hedge funds.
Eloxx Pharmaceuticals Company Profile
Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.
Further Reading
- Five stocks we like better than Eloxx Pharmaceuticals
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- High-Yield Texas Instruments Could Hit New Highs Soon
- What is the S&P/TSX Index?
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.